Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia
Authors:
Open Access
- 1 May 2021
- journal article
- research article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 36 (3) , 617-628
Abstract
Background/Aims: Although it is near concluded that renin-angiotensin system inhibitors do not have a harmful effect on coronavirus disease 2019 (COVID-19), there is no report about whether angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) offer any protective role. This study aimed to compare the association of ARBs and ACEIs with COVID-19-related mortality. Methods: All patients with COVID-19 in Korea between January 19 and April 16, 2020 were enrolled. The association of ARBs and ACEIs with mortality within 60 days were evaluated. A comparison of hazard ratio (HR) was performed between COVID-19 patients and a retrospective cohort of pneumonia patients hospitalized in 2019 in Korea. Results: Among 10,448 COVID-19 patients, ARBs and ACEIs were prescribed in 1,231 (11.7%) and 57 (0.6%) patients, respectively. After adjusting for age, sex, and history of comorbidities, the ARB group showed neutral association (HR, 1.034; 95% CI, 0.765 to 1.399; p = 0.8270) and the ACEI groups showed no significant associations likely owing to the small population size (HR, 0.736; 95% CI, 0.314 to 1.726; p = 0.4810). When comparing HR between COVID-19 patients and a retrospective cohort of patients hospitalized with pneumonia in 2019, the trend of ACEIs showed similar benefits, whereas the protective effect of ARBs observed in the retrospective cohort was absent in COVID-19 patients. Meta-analyses showed significant positive correlation with survival of ACEIs, whereas a neutral association between ARBs and mortality. Conclusions: Although ARBs or ACEIs were not associated with fatal outcomes, potential beneficial effects of ARBs observed in pneumonia were attenuated in COVID-19.Keywords
Funding Information
- Korea Disease Control and Prevention Agency (#4838-330-320-01)
- Seoul National University Hospital (#04-2020-0030)
This publication has 55 references indexed in Scilit:
- The Angiotensin-Converting Enzyme Inhibitor Captopril Inhibits Poly(Adp-Ribose) Polymerase Activation and Exerts Beneficial Effects in an Ovine Model of Burn and Smoke InjuryShock, 2011
- Healthy User and Related Biases in Observational Studies of Preventive Interventions: A Primer for PhysiciansJournal of General Internal Medicine, 2011
- The impact of statins, ace inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohortPharmacoepidemiology and Drug Safety, 2009
- Choosing an optimal method to combineP‐valuesStatistics in Medicine, 2009
- ACE mediates ventilator-induced lung injury in ratsviaangiotensin II but not bradykininEuropean Respiratory Journal, 2007
- Blockade of AT1 Receptor Reduces Apoptosis, Inflammation, and Oxidative Stress in Normotensive Rats with Intracerebral HemorrhageThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Role of the renin-angiotensin system in ventilator-induced lung injury: an in vivo study in a rat modelThorax, 2007
- ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENTCardiovascular Research, 2007
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005
- Imbalance of T-Cell Subsets in Angiotensin II–Infused Hypertensive Rats With Kidney InjuryHypertension, 2003